Faculty Profiles - MIURA Naoki

Papers - MIURA Naoki

Division display 121 - 140 of about 184 ／ All the affair displays >>

Kikuchi K, Uchikado H, Miura N, Morimoto Y, Ito T, Tancharoen S, Miyata K, Sakamoto R, Kikuchi C, Iida N, Shiomi N, KuramotoT, Miyagi N, Kawahara K . HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development. . Exp Ther Med2 ( 5 ) 767 - 770 2011.5Reviewed

三浦直樹 . ダイナミックCT造影検査による門脈体循環シャント症例の診断. . 鹿児島県獣医師会雑誌26 ( 1 ) 20 - 21 2011.3

Kawaguchi H, Miyoshi N, Miura N, Fujiki M, Horiuchi M, Izumi Y, Miyajima H, Nagata R, Misumi K, Takeuchi T, Tanimoto A, Yoshida H . Microminipig, a Non-rodent Experimental Animal Optimized for Life Science Research:Novel Atherosclerosis Model Induced by High Fat and Cholesterol Diet. . J Pharmacol Sci.115 ( 2 ) 115 - 121 2011.2Reviewed

Kikuchi K*, Miura N*, (*These authors are equally contributed.) Morimoto Y, Ito T, Tancharoen S, Miyata K, Kikuchi C, Iida N, Takeshige N, Uchikado H, Miyagi N, Shiomi N, KuramotoT, Hashiguchi T, Maruyama I, Morioka M, Kawahara K. . Beneficial Effects of the Free Radical Scavenger Edaravone (Radicut) in Neurologic Diseases. . J Neurol Neurophysiol 1 ( Special Issue 1 ) 1 - 5 2011.1Reviewed

田崎由実, 三浦直樹, 桃井康行 . 鹿児島県で多発するイヌのシリカ結石についての報告 . ペット栄養学会誌14 ( 0 ) Suppl_73 - Suppl_74 2011Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：日本ペット栄養学会

シリカ結石はイヌではまれな尿石とされている。今回、我々は鹿児島県を中心にシリカ尿結石について疫学調査を行った。その結果、鹿児島県内の獣医師やオーナーに対するアンケート調査において、鹿児島県を中心とする地域でシリカ尿結石が多くみられ、その発生の要因として飲料水との関係が示唆された。そこで鹿児島県内の水道水中のシリカ濃度を測定したところ、他地域と比較して著しく高値を示した。またミネラルウォーターについても同様に、鹿児島県が採水地の製品でシリカ濃度が高値のものがあった。実験的にシリカを高濃度に含む水道水の飲水により尿中シリカ濃度の上昇は見られなかったが、疫学調査から、シリカ濃度の低い水を飲水として使用することがシリカ結石発生の予防となると推測した。

DOI： 10.11266/jpan.14.Suppl_73

CiNii Research

Kikuchi, K., Uchikado, H., Miura, N., Morimoto, Y., Ito, T., Tancharoen, S., Miyata, K., Sakamoto, R., Kikuchi, C., Iida, N., Shiomi, N., Kuramoto, T., Miyagi, N., Kawahara, K.-I. . HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review) . Experimental and Therapeutic Medicine2 ( 5 ) 767 - 770 2011Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB I plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant patients. We hypothesize that inhibition of HMGB1 release rescues patients with SCI. Taken together, our findings suggest that anti-HMGB1 monoclonal antibodies or short hairpin RNA-mediated HMGB1 could be administered for spinal cord repair in SCI patients.

DOI： 10.3892/etm.2011.310

Kikuchi, K., Uchikado, H., Miyagi, N., Morimoto, Y., Takashi, I., Tancharoen, S., Miura, N., Miyata, K., Sakamoto, R., Kikuchi, C., Iida, N., Shiomi, N., Kuramoto, T., Kawahara, K.-I. . Beyond neurological disease: New targets for edaravone (Review) . International Journal of Molecular Medicine28 ( 6 ) 899 - 906 2011Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

Free radicals play major roles in the pathogenesis of tissue damage in many diseases and clinical conditions, and the removal of free radicals may offer a treatment option. Several modulators of free radical scavenger pathways have been developed and some have progressed to clinical trials. One such agent, edaravone, was approved in 2001 in Japan for the treatment of cerebral infarction. It has since been shown that edaravone can diffuse into many organs and, in addition to its effects on hydroxyl radical removal, edaravone modulates inflammatory processes, matrix metalloproteinase levels, nitric oxide production, apoptotic cell death, and necrotic cell death. Edaravone also exerts protective effects in a number of animal models of disease and tissue damage, including models of myocardial, lung, intestinal, liver, pancreatic and renal injury. Together with the proven safety of edaravone following 9 years of use as a modulator of free radical scavenging pathways in neurological disease, these additional effects of edaravone suggest that it may offer a novel treatment for several non-neurological diseases and clinical conditions in humans.

DOI： 10.3892/ijmm.2011.795

Meng, X., Kawahara, K.-I., Miyanohara, H., Yoshimoto, Y., Yoshinaga, K., Noma, S., Kikuchi, K., Morimoto, Y., Ito, T., Oyama, Y., Yoshinaga, N., Shrestha, B., Chandan, B., Mera, K., Tada, K.-I., Miura, N., Ono, Y., Takenouchi, K., Maenosono, R., Nagasato, T., Hashiguchi, T., Maruyama, I. . 1,5-anhydro-D-fructose: A natural antibiotic that inhibits the growth of gram-positive bacteria and microbial biofilm formation to prevent nosocomial infection . Experimental and Therapeutic Medicine2 ( 4 ) 625 - 628 2011Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

Nosocomial infections caused by microbial opportunistic infections or microbial biofilms may occur during hospitalization and increase patient morbidity, mortality and health care costs. Artificial antibiotic agents were initially used to prevent infection; however, the high prevalence of nosocomial infections has resulted in their excessive use, which has led to microbial resistance to these agents. The increase in microbial resistance to antibiotics and the development of antibiotic agents may be the cause of the production of other microbial resistance. Thus, natural compounds that have no adverse side effects would be a preferred treatment modality. Recently, the monosaccharide 1,5-anhydro-D-fructose (1,5-AF), a natural plant compound derived from starch, has been found to have multifunctional properties, including antioxidant, antiplatelet aggregation by thrombin and anti-inflammatory activities. The results of the present study demonstrate that 1,5-AF suppressed the growth of coagulase-negative staphylococci on the hands as well as the growth of Staphylococcus epidermidis, which is a cause of opportunistic infections. Furthermore, 1,5-AF suppressed biofilm formation by the methicillin-resistant Staphylococcus aureus. In conclusion, 1,5-AF is a natural compound that may be effective in preventing nosocomial infections, without causing adverse side effects.

DOI： 10.3892/etm.2011.245

Kawaguchi Hiroaki, Miyoshi Noriaki, Miura Naoki, Horiuchi Masahisa, Ono Tomoji, Murakoshi Michiaki, Nishino Hoyoku, Nagata Ryoichi, Sahara Hisashi, Tanimoto Akihide, Yamada Kazuhiko, Yoshida Hiroki . Microminipig: research models to break through cardiovascular disease . JOURNAL OF PHARMACOLOGICAL SCIENCES115 49P 2011Reviewed International journal

Kikuchi, K., Kawahara, K.-I., Uchikado, H., Miyagi, N., Kuramoto, T., Miyagi, T., Morimoto, Y., Ito, T., Tancharoen, S., Miura, N., Takenouchi, K., Oyama, Y., Shrestha, B., Matsuda, F., Yoshida, Y., Arimura, S., Mera, K., Tada, K.-I., Yoshinaga, N., Maenosono, R., Ohno, Y., Hashiguchi, T., Maruyama, I., Shigemori, M. . Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review) . Experimental and Therapeutic Medicine2 ( 5 ) 771 - 775 2011Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

Edaravone was originally developed as a potent free radical scavenger and has been widely used to treat cerebral infarction in Japan since 2001. Several free radical scavengers have been developed and some of them have progressed to clinical trials for the treatment of cerebral infarction. One such scavenger, edaravone, has been approved by the regulatory authority in Japan for the treatment of patients with cerebral infarction. Of particular interest is the ability of edaravone to diffuse into the central nervous system in various neurologic diseases. Aside from its hydroxyl radical scavenging effect, edaravone has been found to have beneficial effects on inflammation, matrix metalloproteinases, nitric oxide production and apoptotic cell death. Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. The proven safety of edaravone following 9 years of use as a free radical scavenger suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.

DOI： 10.3892/etm.2011.281

KIKUCHI KIYOSHI, KAWAHARA KO-ICHI, UCHIKADO HISAAKI, MIYAGI NAOHISA, KURAMOTO TERUKAZU, MIYAGI TOMOYA, MORIMOTO YOKO, ITO TAKASHI, TANCHAROEN SALUNYA, MIURA NAOKI, MIYATA KEI, KIKUCHI CHIEMI, SAKAMOTO ROKUDAI, SHIOMI NAOTO, HASHIGUCHI TERUTO, MARUYAMA IKURO, TOKUTOMI TAKASHI, SHIGEMORI MINORU . Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced apoptosis in ischemic neuronal injury in PC12 cells . Neurotraumatology33 ( 2 ) 241 - 243 2010.12Reviewed International journal

Kikuchi K, Kawahara KI, Miyagi N, Uchikado H, Kuramoto T, Morimoto Y, Tancharoen S, Miura N, Takenouchi K, Oyama Y, Shrestha B, Matsuda F, Yoshida Y, Arimura S, Mera K, Tada KI, Yoshinaga N, Maenosono R, Ohno Y, Hashiguchi T, Maruyama I, Shigemori M. . Edaravone: A new therapeutic approach for the treatment of acute stroke. . Med Hypotheses.75 ( 6 ) 583 - 585 2010.12Reviewed

Miyoshi N, Horiuchi M, Inokuchi Y, Miyamoto Y, Miura N, Tokunaga S, Fujiki M, Izumi Y, Miyajima H, Nagata R, Misumi K, Takeuchi T, Tanimoto A, Yasuda N, Yoshida H and Kawaguchi H. . Novel Microminipig Model of Atherosclerosis by High Fat and High Cholesterol Diet, Established in Japan. . In Vivo24 ( 5 ) 671 - 680 2010.9Reviewed

Kikuchi K, Kawahara K, Tsuji C, Tajima Y, Kuramoto T, Shihara M, Koga Y, Shiomi N, Uchikado H, Morimoto Y, Miura N, Mera K, Ohno Y, Miyagi N, Hashiguchi T, Maruyama I, Hayabuchi N, Nakayama K, Shigemori M . Post mortem contrast-enhanced computed tomography in a case of sudden death from acute pulmonary thromboembolism. . Experimental and Therapeutic Medicine1 ( 3 ) 503 - 505 2010.5Reviewed

KikuchiK, Kawahara K, Biswas KK, Ito T, Tancharoen S, Shiomi N, Koda Y, Matsuda F, Morimoto Y, Oyama Y, Takenouchi K, Miura N, Arimura N, Nawa Y, Arimura S, Jie MX, Shrestha B, Iwata M, Mera K, Sameshima H, Ohno Y, Maenosono R, Tajima Y, Uchikado H, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi T, Maruyama I . MGB1: A new marker for estimation of the postmortem interval. . Experimental and Therapeutic Medicine1 ( 1 ) 109 - 111 2010.1Reviewed

Shrestha B*, Hashiguchi T*, Ito T*, Miura N*,(*These authors are equally contributed.) Takenouchi K, Oyama Y, Kawahara K, Tancharoen S, Ki-I Y, Arimura N, Yoshinaga N, Noma S, Shrestha C, Nitanda T, Kitajima S, Arimura K, Sato M, Sakamoto T, Maruyama I. . B cell-derived vascular endothelial growth factor a promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. . Journal of Immunology184 ( 9 ) 4819 - 4826 2010Reviewed

Kikuchi, K., Kawahara, K., Biswas, K.K., Ito, T., Tancharoen, S., Shiomi, N., Koda, Y., Matsuda, F., Morimoto, Y., Oyama, Y., Takenouchi, K., Miura, N., Arimura, N., Nawa, Y., Arimura, S., Jie, M.X., Shrestha, B., Iwata, M., Mera, K., Sameshima, H., Ohno, Y., Maenosono, R., Tajima, Y., Uchikado, H., Kuramoto, T., Nakayama, K., Shigemori, M., Yoshida, Y., Hashiguchi, T., Maruyama, I. . HMGB1: A new marker for estimation of the postmortem interval . Experimental and Therapeutic Medicine1 ( 1 ) 109 - 111 2010Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

Estimation of the postmortem interval (PMI) is one of the most important tasks in forensic medicine Numerous methods have been proposed for the determination of the time since death by chemical means High mobility group box-1 (HMGB1), a nonhistone DNA-binding protein is released by eukaryotic cells upon necrosis Postmortem serum levels of HMGB1 of 90 male Wistar rats stored at 4 14 and 24 degrees C since death were measured by enzyme-linked immunosorbent assay The serum HMGB1 level showed a time-dependent increase up to seven days at 4 degrees C At 14 degrees C, the HMGB1 level peaked at day 3, decreased at day 4, and then plateaued At 24 degrees C, the HMGB1 level peaked at day 2, decreased at day 3, and then plateaued Our findings suggest that HMGB1 is related to the PMI in rats

DOI： 10.3892/etm_00000019

Kawaguchi Hiroaki, Miyoshi Noriaki, Fujiki Makoto, Miura Naoki, Horiuchi Masahisa, Itoh Katzuhiko, Kaneko Naoki, Miyajima Hiroaki, Nagata Ryoichi, Misumi Kazuhiro, Yasuda Nobuhiro . Microminipig atherosclerosis model by high fat and cholesterol-diet . JOURNAL OF PHARMACOLOGICAL SCIENCES112 34P 2010Reviewed International journal

Kikuchi K, Kawahara K, Biswas KK, Ito T, Tancharoen S, Morimoto Y, Matsuda F, Oyama Y, Takenouchi K, Miura N, Arimura N, Nawa Y, Meng X, Shrestha B, Arimura S, Iwata M, Mera K, Sameshima H, Ohno Y, Maenosono R, Yoshida Y, Tajima Y, Uchikado H, Kuramoto T, Nakayama K, Shigemori M, Hashiguchi T, Maruyama I. . Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced cell death in ischemic neuronal injury in PC12 cells. . Biochem Biophys Res Commun385 ( 2 ) 132 - 136 2009.7Reviewed

Kikuchi K, Kawahara K, Tancharoen S, Matsuda F, Morimoto Y, Ito T, Biswas KK, Takenouchi K, Miura N, Oyama Y, Nawa Y, Arimura N, Iwata M, Tajima Y, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi T, Maruyama I. . The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. . J Pharmacol Exp Ther326 ( 3 ) 865 - 874 2009.6Reviewed

　 PREV - NEXT 　

<MIURA Naoki>

Papers - MIURA Naoki